Hwang Seong-Hye, Lee Sangchul, Park Jee Yoon, Jeon Jessie Sungyun, Cho Young-Jae, Kim Sejoong
Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam 13620, Korea.
Department of Urology, Seoul National University College of Medicine, Seoul 03080, Korea.
Micromachines (Basel). 2021 Feb 21;12(2):215. doi: 10.3390/mi12020215.
Organ-on-a-chip (OoC) is an exponential technology with the potential to revolutionize disease, toxicology research, and drug discovery. Recent advances in OoC could be utilized for drug screening in disease models to evaluate the efficacy of new therapies and support new tools for the understanding of disease mechanisms. Rigorous validation of this technology is required to determine whether OoC models may represent human-relevant physiology and predict clinical outcomes in target disease models. Achievements in the OoC field could reveal exciting new avenues for drug development and discovery. This review attempts to highlight the benefits of OoC as per our understanding of the cellular and molecular pathways in lung and kidney cancer models, and discusses the challenges in evaluating drug efficacy.
器官芯片(OoC)是一项具有指数级增长潜力的技术,有望彻底改变疾病、毒理学研究及药物研发。器官芯片领域的最新进展可用于疾病模型中的药物筛选,以评估新疗法的疗效,并为理解疾病机制提供新工具。需要对该技术进行严格验证,以确定器官芯片模型是否能够代表与人类相关的生理学特征,并预测目标疾病模型中的临床结果。器官芯片领域的成果可能会为药物开发和发现揭示令人兴奋的新途径。本综述旨在根据我们对肺癌和肾癌模型中细胞及分子途径的理解,突出器官芯片的优势,并讨论评估药物疗效时所面临的挑战。